	US 11,913,051 B2
	Engineered and fully-functional customized glycoproteins
Amirreza Faridmoayer, Zurich (CH); Manuela Mally, Watt (CH); and Rainer Follador, Zurich (CH)
Assigned to LimmaTech Biologics AG, Schlieren (CH)
Appl. No. 16/625,579
Filed by LimmaTech Biologics AG, Schlieren (CH)
PCT Filed Jun. 28, 2018, PCT No. PCT/EP2018/067494 § 371(c)(1), (2) Date Dec. 20, 2019, PCT Pub. No. WO2019/002512, PCT Pub. Date Jan. 3, 2019.
Claims priority of provisional application 62/527,466, filed on Jun. 30, 2017.
Prior Publication US 2021/0332403 A1, Oct. 28, 2021
Int. Cl. C12P 21/00 (2006.01); C12N 1/10 (2006.01); C12N 9/10 (2006.01); C12R 1/90 (2006.01)

CPC C12P 21/005 (2013.01) [C12N 1/105 (2021.05); C12N 9/1029 (2013.01); C12N 9/1051 (2013.01); C12N 9/1081 (2013.01); C07K 2319/04 (2013.01); C07K 2319/05 (2013.01); C12R 2001/90 (2021.05); C12Y 203/01003 (2013.01); C12Y 204/01022 (2013.01); C12Y 204/01101 (2013.01); C12Y 204/01143 (2013.01); C12Y 204/99006 (2013.01)]

49 Claims

1. A Leishmania host cell comprising:

a. a recombinant nucleic acid encoding a target protein; and

b. a recombinant nucleic acid encoding a heterologous glycosyltransferase, wherein the heterologous glycosyltransferase is an N-acetyl glucosamine transferase that is not from Leishmania and/or galactosyltransferase that is not from Leishmania; wherein the heterologous glycosyltransferase comprises a signal and/or retention sequence, wherein the signal sequence is capable of targeting the heterologous glycosyltransferase to the secretory pathway of the Leishmania host cell, and wherein the retention sequence is capable of retaining the heterologous glycosyltransferase in the Golgi apparatus.